Disruptive Behavior Disorder Clinical Trial
Official title:
Risperidone in the Treatment of Children and Adolescents With Conduct and Other Disruptive Behavior Disorders - an Open Label Follow-up Trial of CR002020
The primary purpose of this study is to document the long-term safety of an oral formulation of risperidone in the treatment of children and adolescents with conduct and other disruptive behavior disorders. Data on the efficacy of the drug will also be collected. Only patients who were enrolled in the previous related study would be eligible to participate.
This is an open-label study of an oral formulation of risperidone to be taken daily over 12 months by children and adolescents with conduct and other disruptive behavior disorders. It is an extension of a randomized, double-blind study (RIS-INT-79) comparing risperidone with placebo over 6 months in patients who had already shown response to the medication for a period of 12 weeks. Efficacy assessments include: the Conduct Problem subscale of the Nisonger Child Behavior Rating Form (N-CBRF), a measure of symptoms of conduct and other disruptive behavior disorders; Visual Analogue Scale for the most troublesome symptom (VAS-MS), a scale ranging from not troublesome to extremely troublesome; Clinical Global Impression-Severity of Illness (CGI-Severity), a measure of overall severity of illness; Children's Global Assessment Scale (C-GAS), as assessment overall functioning. Safety evaluations include incidence of adverse events, physical examinations, laboratory tests (biochemistry, hematology, and urinalysis), and electrocardiograms (ECGs). Oral risperidone solution (1milligram/milliliter) daily for 1year. For patients weighing at least 50kg, start dose is 0.5ml/day. At investigator's discretion, dose may be increased (maximum 1.5ml/d over 5 days). Patients under 50kg start at 0.25ml/d, increased, if required, to maximum 0.75ml/d. ;
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00250354 -
A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation
|
Phase 3 | |
| Completed |
NCT03698240 -
Mindfulness-based Program for Children With Disruptive Behavior Disorder
|
N/A | |
| Completed |
NCT01750996 -
Strongest Families Finland Canada: Family-based Prevention and Treatment Program of Early Childhood Disruptive Behavior
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06373484 -
Matching Assessment and Treatment for Children With Disruptive Behaviour and Their Parents
|
N/A | |
| Completed |
NCT02783560 -
Behavioral Sleep Intervention in Children With Disruptive Behaviors
|
N/A | |
| Recruiting |
NCT02812537 -
Clinical and Social Trajectories of Children and Adolescents With Disruptive Behavior
|
||
| Recruiting |
NCT04298437 -
Addressing Depression and Positive Parenting Techniques (ADAPT)
|
N/A | |
| Completed |
NCT02704221 -
Enhancing the Outcomes of a Behavioral Parent Training Intervention
|
N/A | |
| Completed |
NCT02488499 -
Addressing Behaviour and Treatment Effectiveness Project (A.B.A.T.E. Project)
|
N/A | |
| Recruiting |
NCT04113161 -
Navigating Resource-Constrained Systems and Communities to Promote the Behavioral Health of Black Youth
|
N/A | |
| Enrolling by invitation |
NCT05425381 -
Improving Social, Emotional, Behavioral, and Academic Functioning
|
N/A | |
| Completed |
NCT03796663 -
Mindful Parenting and Parent Training Program Study
|
N/A | |
| Completed |
NCT00266552 -
A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation
|
Phase 3 |